Australia's most trusted
source of pharma news
Thursday, 13 November 2025
Posted 12 November 2025 AM
CSL's life-changing haemophilia B gene therapy Hemgenix - the world's second most expensive drug with an estimated price tag of $5.3 million for a one-time treatment - has won a recommendation from MSAC, but a battle over price is already brewing.
Following a knockback last year, MSAC has come to the party, advising Health Minister Mark Butler that it supports public funding for Hemgenix under the National Blood Agreement, contingent on pricing.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.